Fig. 2 | Scientific Reports

Fig. 2

From: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors

Fig. 2

Proportion of patients with improved, stable, and deteriorated domains and functional scales during immune checkpoint inhibitor (ICI) therapy. Baseline scores were obtained on day 1 after the initial ICI therapy. The minimally important difference (MIC) of each scale was defined as 10 points in the EORTC QLQ-C30 and half the standard deviation (SD) of the baseline score in the FACT-G and SF-8. Increased and decreased ≥ MIC from the baseline score during ICI therapy were considered ‘improved’ and ‘deteriorated’, respectively. EORTC QLQ-C30, European organization for research and treatment of cancer quality of life questionnaire-core 30; FACT-G, functional assessment of cancer therapy-general; SF-8 multi-item short form-8.

Back to article page